<DOC>
	<DOCNO>NCT00888472</DOCNO>
	<brief_summary>Extracorporeal leukocytapheresis ( LCAP ) granulocytapheresis ( GCAP ) use treatment patient rheumatoid arthritis ulcerative colitis show promising safety efficacy . LCAP GCAP seem effective steroid-resistant inflammation . The investigator already report safety efficacy GCAP refractory asthma expect beneficial effect LCAP refractory asthma . In study , order improve therapeutic effect LCAP increase quantity leukocytes remove , investigator conduct clinical study investigate safety efficacy high-dose LCAP perform use large filter increase dose blood volume per body weight treat , possible therapy refractory asthma .</brief_summary>
	<brief_title>Safety Efficacy High-dose Leukocytapheresis Using Large Filter Refractory Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<criteria>Patients fulfil 2001 criterion refractory asthma American Thoracic Society . Pregnant woman . Patients severe cardiovascular disease . Patients infective disease . Patients leukocytopenia anemia .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>Extracorporeal leukocytapheresis</keyword>
</DOC>